Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K K Ray

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Diabetes & Metabolism|March 29, 2017
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trialB Cariou, L A Leiter, D Müller-Wieland, et al.
Journal of Ayurveda and Integrative Medicine|June 11, 2017
Mercury based drug in ancient India: The red sulfide of mercury in nanoscalePriyabrata Mukhi, Swapna Sarita Mohapatra, M Bhattacharjee, et al.
Revista Clinica Espanola|November 29, 2024
Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI studyJ M Mostaza, L García-Ortiz, M A Suárez Tembra, et al.
Lancet (London, England)|July 9, 2010
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, N Sarwar, P Gao, et al.
Revista Clinica Espanola|July 17, 2025
Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI studyJ M Mostaza, C Lahoz, M G de Yébenes Castro, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Diabetes & Metabolism|March 29, 2017
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trialB Cariou, L A Leiter, D Müller-Wieland, et al.
Journal of Ayurveda and Integrative Medicine|June 11, 2017
Mercury based drug in ancient India: The red sulfide of mercury in nanoscalePriyabrata Mukhi, Swapna Sarita Mohapatra, M Bhattacharjee, et al.
Revista Clinica Espanola|November 29, 2024
Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI studyJ M Mostaza, L García-Ortiz, M A Suárez Tembra, et al.
Lancet (London, England)|July 9, 2010
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, N Sarwar, P Gao, et al.
Revista Clinica Espanola|July 17, 2025
Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI studyJ M Mostaza, C Lahoz, M G de Yébenes Castro, et al.
Pageof 4